Evidence of Plasma Biomarkers Indicating High Risk of Dementia in Cognitively Normal Subjects with a History of Stroke, a Family History of Alzheimer's Disease, Diabetes Mellitus, End‐stage Renal Disease and Obstructive Sleep Apnea. (20th December 2022)

• Record Type: Journal Article
• Authors: Pai, Ming‐Chyi; Yang, Shieh‐Yueh
• Is Part Of: Alzheimer's & dementia. Volume 18(2022)Supplement 6
• Page Start: n/a
• Page End: n/a
• Publication Date: 2022-12-20
• Subjects: Alzheimer's disease -- Periodicals; Alzheimer Disease -- Periodicals; Dementia -- Periodicals; Démence; Maladie d'Alzheimer; Périodique électronique (Descripteur de forme); Ressource Internet (Descripteur de forme); 616.83
• DOI: 10.1002/alz.062658
• Languages: English
• ISSNs: 1552-5260

Abstract

Abstract: Background: Subjects with comorbidities are at risk for neurodegeneration. There is a lack of a direct relationship between comorbidities and neurodegeneration. Method: In this study, immunomagnetic reduction (IMR) assays were utilized to assay plasma Aβ1‐42 and total tau protein (T‐Tau) levels in poststroke (PS, n = 27), family history of Alzheimer's disease (ADFH, n = 35), diabetes (n = 21), end‐stage renal disease (ESRD, n = 41), obstructive sleep apnea (OSA, n = 20), Alzheimer's disease (AD, n = 65). Thirty‐seven healthy controls (HCs) were enrolled. Result: The measured concentrations of plasma Aβ1‐42 were 14.26±1.42, 15.43±1.76, 15.52±1.60, 19.74±2.92, 16.52±0.59, 15.97±0.54 and 20.06±3.09 pg/ml in HC, PS, ADFH, diabetes, ESRD, OSA and AD groups, respectively. The corresponding concentrations of plasma T‐Tau were 15.13±3.62, 19.29±8.01, 17.93±6.26, 19.74±2.92, 21.54±2.72, 20.17±2.77 and 41.24±14.64 pg/ml. The plasma levels of Aβ1‐42 and T‐Tau in the PS, ADFH, diabetes, ESRD and OSA groups were relatively high compared to HC group but were lower than AD group. Conclusion: This evidence indicates the high risk for dementia in these groups from the perspective of plasma biomarkers.